Doximity, Inc. Reveals Retreat In Q3 Profit

Doximity posted Q3 GAAP profit of $61.55 million ($0.31/share) versus $75.19 million ($0.37) a year ago, while adjusted earnings were $91.14 million ($0.46/share). Revenue rose 9.8% year-over-year to $185.05 million from $168.60 million. Management guided next-quarter revenue to $143 million–$144 million, signaling more modest near-term top-line expectations despite year-over-year growth in the quarter; the print is therefore mixed for investors—top-line expansion but lower GAAP profitability and conservative near-term guidance.

Analysis

Market structure: Doximity’s print (revenue +9.8% y/y to $185.0M but GAAP EPS down ~16%) and guidance of $143–144M for next quarter implies an approximate ~22% q/q revenue dip, signaling near-term demand softness or strong seasonality. Winners: larger, diversified healthcare-software vendors (e.g., VEEV) and pharma digital ad vendors that can outspend smaller networks; losers: pure-play physician engagement platforms that lack diversified monetization. Pricing power likely weak near-term as customers push back on ad/spend and recruitment budgets.

Risk assessment: Tail risks include regulatory action on physician-data monetization or a material breach (10–20% downside shock scenario), a larger-than-expected ad-spend retrenchment, or accelerated churn if product conversion stalls. Time horizons: immediate (days) — elevated IV and swing risk; short-term (3 months) — guidance execution and seasonality verification; long-term (6–24 months) — outcome driven by product monetization and cohort retention improvements. Hidden dependency: revenue skew to a small set of pharma/advertisers could amplify volatility if 1–2 customers pull back (>15% revenue impact).

Trade implications: If DOCS trades down >10% intraday, that creates a tactical long entry (buy the dip) with 6–12 month upside if retention holds; otherwise use 90–120 day put spreads to cap downside in the 8–20% range. Consider pair-trade: long VEEV (1–2% portfolio) / short DOCS (1–2%) for 3–6 months to play secular enterprise strength over niche ad exposure. Option strategies: sell 30–45 day covered calls at ~10–15% OTM if holding equity to collect 2–3% monthly income while waiting for clarity.

Contrarian angles: The market may be over-focusing on GAAP EPS and next-quarter guide while ignoring adjusted operating momentum (adjusted EPS $0.46); if management proves retention and ARPU improvement, upside of +25–40% over 6–12 months is possible. Historical parallels: platform companies with mixed monetize/recruiting models often trade down on guides then rebound after two positive prints; watch churn and Large-Customer concentration metrics as the binary catalysts that could flip sentiment quickly.

Key Decisions for Investors

• If DOCS trades down >10% intraday, establish a 2–3% long position (portfolio weight) with a stop-loss at -15% and a target of +30% over 6–12 months, reassess after next two quarterly prints.
• Buy a 90–120 day put spread on DOCS sized to 1% of portfolio: buy 5–10% OTM puts and sell 15–20% OTM puts to hedge a downside move between 8–20% while capping cost; roll or unwind after guidance verification.
• Initiate a 1–2% long VEEV / 1–2% short DOCS pair for 3–6 months to express preference for diversified enterprise healthcare software over ad/recruiting-exposed platforms; rebalance after next earnings.
• If holding DOCS stock, sell 30–45 day covered calls ~10–15% OTM to generate ~2–3% monthly income and reduce carry while waiting for clearer retention and monetization signs; roll monthly if implied volatility stays elevated.